6-K 1 form6k.htm 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 6-K



Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the month of June 2019

Commission File Number 001-38716



GAMIDA CELL LTD.
(Translation of registrant’s name into English)



Nahum Heftsadie Street
Givaat Shaul, Jerusalem 91340 Israel
(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):


Appointment of Tracey Lodie, Ph.D. as Chief Scientific Officer

On June 5, 2019, Gamida Cell Ltd. (the Company) announced the appointment of Tracey Lodie, Ph.D. as chief scientific officer. A copy of the Companys press release with this announcement is attached to this Report on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.

Exhibits
   
   
 
Press Release, dated June 5, 2019: Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer
   
     
   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


       
   
GAMIDA CELL LTD.
     
June 5, 2019
 
By:
/s/ Shai Lankry
     
Shai Lankry
     
Chief Financial Officer